Engineered bacteriophages for treatment of a patient with a disseminated drug resistant Mycobacterium abscessus

By R. Dedrick, Carlos A. Guerrero-Bustamante, R. Garlena, Daniel A. Russell, K. Ford, K. Harris, K. Gilmour, J. Soothill, D. Jacobs-Sera, R. Schooley and 2 more. 2019

1,238 citations recorded by the source corpus.

A 15-year-old patient with cystic fibrosis with a disseminated Mycobacterium abscessus infection was treated with a three-phage cocktail following bilateral lung transplantation. Effective lytic phage derivatives that efficiently kill the infectious M. abscessus strain were developed by genome engineering and forward genetics. Intravenous phage treatment was well tolerated and associated with objective clinical improvement, including sternal wound closure, improved liver function, and substantial resolution of infected skin nodules. Clinical use of engineered bacteriophages for the treatment of disseminated mycobacterial infection.

Subfields: Ecology, Epidemiology, Microbiology

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Ecology

In Epidemiology

Graham F. Hatfull

Citations in the corpus

Impact of antibiotics on the human microbiome and consequences for host health (2022, background): “ment in a patient with cystic fibrosis (Dedrick et al., 2019).”
Pseudomonas aeruginosa: pathogenesis, virulence factors, antibiotic resistance, interaction with host, technology advances and emerging therapeutics (2022, background): “Engineered bacteriophages BPsΔ33HTH_HRM10 and D29_HRMGD40 cocktail cured a cystic fibrosis patient with a disseminated drug-resistant Mycobacterium abscessus, which shows that the therapeutics of engineered phages to break the evolutionary constraints, holding great potential to create the next-gene”
Toward a Phage Cocktail for Tuberculosis: Susceptibility and Tuberculocidal Action of Mycobacteriophages against Diverse Mycobacterium tuberculosis Strains (2021, methodology): “Whether such therapy might be broadly applicable or restricted to a narrow spectrum of disease states is not clear, but with the excellent safety profile of phages in humans (33, 58), these questions now can be addressed.”
Bacteriophage targeting of gut bacterium attenuates alcoholic liver disease (2019, neutral): “A 0.02 mg/ml final concentration of CylA (27–412) was added to the elution fraction and allowed to incubate at room temperature overnight to remove the leader peptide.”
Engineering Phage Host-Range and Suppressing Bacterial Resistance through Phage Tail Fiber Mutagenesis (2019, background): “Moreover, phage therapy has successfully been used for compassionate care cases when all antibiotic treatment options have failed (Dedrick et al., 2019; Schooley et al., 2017).”